Receptor-mediated targeted
tumor therapy is an important applied consequence of the studies on the genetic causes of
cancer. These
therapy concepts have to be evaluated in novel animal models that reflect the molecular aberrations found in human
tumors. Here we introduce an animal model that allows the evaluation of drugs directed against a surface receptor that is frequently altered in primary human
adenocarcinomas.
Tumor toxins are
polypeptides in which a
tumor cell-specific recognition domain and a toxic effector domain have been joined by
DNA recombination in vitro.
Tumor cell recognition is contributed by a single-chain antibody domain specific for the extracellular domain of the
erbB-2 receptor [scFv(FRP5)] and cytotoxicity by the enzymatically active domain of a bacterial
exotoxin (
exotoxin A from Pseudomonas aeruginosa). The
erbB-2 receptor is overexpressed in many primary human
cancer cells and is a favorable target for directed
tumor therapy. The fusion
protein scFv(FRP5)-exotoxin A has previously been shown to be able to efficiently and specifically kill
erbB-2 receptor-expressing
tumor cells. We have investigated the potential of this
tumor toxin to detect and eliminate metastasizing
tumor cells upon systemic administration. Murine
renal carcinoma cells genetically modified with human
erbB-2 receptor and bacterial
beta-galactosidase genes form large pulmonary
metastases when injected into the tail vein of BALB/c mice. Administration of the
tumor toxin over a 10-day time period starting 1 day after
tumor cell transplantation totally suppressed the formation of
metastases. The treatment of animals 11 days after
tumor cell transplantation, allowing the establishment of many pulmonary
metastases, led to a drastic reduction in their number and size.